What Chemify does

Chemify is a privately held digital chemistry company founded in 2022 as a spin-out from the University of Glasgow, headquartered in Glasgow with an operational footprint extending to the United States (planned Silicon Valley hub) and Japan (via Zeon partnership). The company operates the Chemputation platform, which integrates a generative AI design engine (Quantum Chemputation), an ML-based route optimization tool (ASSEMBLER), and a proprietary universal chemical programming language (χDL) with advanced robotic synthesis infrastructure housed in the Maryhill Chemifarm facility opened in 2025. Together these components execute closed-loop Design-Make-Test-Analyze cycles that translate target molecules into executable, hardware-agnostic chemical code, with the platform reporting a 10x reduction in time from conception to compound synthesis.

Chemify generates revenue primarily through bespoke, multi-year R&D and custom-synthesis collaborations with pharmaceutical, biotechnology, advanced-materials and global-health counterparties, complemented by success-based clinical and regulatory milestones and tiered royalties on compounds the platform designs. Pricing is quote-based and negotiated per program, with disclosed deal economics such as USD $30M+ in payments plus single-digit royalties per molecule in the Prepaire Labs opioid program. Its go-to-market is enterprise sales-led (CBO and SVP Business Development) supplemented by industry conferences, scientific thought leadership, and PR-driven awareness. The company has raised over $90M across a $43M Series A (Aug 2023) and an oversubscribed $50M+ Series B (Oct 2025), with a strategic investment from Zeon Ventures in February 2026 and grant funding from the Bill & Melinda Gates Foundation totaling approximately £2.4M for tuberculosis and malaria drug discovery.

Name

Chemify

Legal name

Chemify Limited

Website

https://chemify.io

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Chemify is a Glasgow-based digital chemistry company that uses its Chemputation platform — combining generative AI design, ML-based route optimization, the proprietary χDL chemical programming language, and automated robotic synthesis — to design and produce small molecules for pharma, biotech, advanced-materials, and global-health partners under bespoke R&D and milestone/royalty agreements.

Ownership category

akta.pro rank

Product category

Digital Chemistry Platform

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Digital chemistry platform
• Automated drug discovery
• Chemical programming language
• Robotic synthesis services
• AI molecular design

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Bespoke R&D Partnerships / Custom Synthesis: Project-based collaborations with pharmaceutical, biotechnology, and materials companies in which Chemify designs, discovers, and synthesises bespoke molecules using the Chemputation platform. Engagements span multiple years and milestones, often including a defined number of design–make cycles or compounds delivered.
2. Success-Based Milestones and Royalties: Multi-year milestone and royalty structures tied to clinical and regulatory progress of compounds Chemify designs for partners. For example, the Prepaire Labs opioid program includes at least USD $30 million in payments and pre-negotiated clinical/regulatory milestones per developed molecule, plus single-digit royalties on resulting products. Similar tiered royalty structures apply to Dewpoint Therapeutics.
3. Option-to-Acquire Compound Rights: For certain partnerships (e.g., Dewpoint), the partner may exercise an option to acquire compounds designed by Chemify; in exchange Chemify receives pre-negotiated, success-driven payments and tiered royalties based on clinical and regulatory milestones.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Core offering

Chemify provides an integrated digital chemistry platform, called Chemputation, that combines ML-based molecular design (Quantum Chemputation), ML-driven route optimization (ASSEMBLER), and a proprietary universal chemical programming language (χDL) executed by advanced robotic synthesis systems. Through its Chemifarm automated synthesis facility in Glasgow, the company delivers fully automated Design–Make–Test–Analyze cycles to pharmaceutical, biotechnology, advanced materials, and global health customers under bespoke R&D partnerships and milestone/royalty-bearing collaboration agreements. Chemify also offers standalone capabilities including upfront Chemputability makeability assessment and massive library derivatization deep into chemical space.

Product overview

Chemify offers a single unified platform called "Chemputation" that combines three interlocking technology modules — Quantum Chemputation (generative AI-driven molecular design), ASSEMBLER (ML-based route optimization using the proprietary reaction database), and χDL (the world's first universal chemical programming language) — executed by Chemify's advanced robotics infrastructure within the Chemifarm automated synthesis facility in Maryhill, Glasgow. The platform is delivered to partners as a digital-to-physical discovery service spanning custom synthesis, scale-up for preclinical testing, Chemputability makeability scoring, and massive library derivatization deep into chemical space. Together these modules enable fully automated Design-Make-Test-Analyze cycles that translate target molecules into executable chemical code run on robotic systems.

Differentiator

Problem solved

Functional benefit

Brands

• Chemifarm: Chemify's branded fully automated synthesis facility (Chemputation facility); the first Chemifarm opened in Maryhill, Glasgow in 2025.
• Chemputation
• χDL (ChiDL)
• ASSEMBLER

Products and services

• Chemputation Technology Platform Integrated digital chemistry platform combining Quantum Chemputation (ML-based generative molecular design), ASSEMBLER (route optimization), and χDL (universal chemical programming language), executed by advanced robotic systems to deliver fully automated Design-Make-Test-Analyze cycles for pharmaceutical, biotechnology, materials, and global health partners.
• Chemputability Makeability Assessment Algorithmically scores each molecule's Chemputability (practical makeability) before synthesis by comparing reaction steps against Chemify's database of tens of thousands of validated, optimized, and automated reactions; suggests Chemputable alternative structures when designs are not readily synthesizable.
• Massive Library Derivatization Generates large derivatized libraries from established synthetic routes encoded in χDL, incorporating physicochemical parameters, druglike parameters, and makeability considerations; enables deep chemical-space exploration and gram-scale automated synthesis from a key advanced intermediate.

Quantifiable outcome

• 10x reduction in time from initial conception to compound synthesis via Chemputation platform
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship co-development partner for cardiometabolic pipeline, flagship strategic partner for opioid programs, flagship strategic partner for oncology and neurodegeneration, core co-development partner for tb program and foundational academic partner (spin-out origin).

• Sanacorflagship co-development partner for cardiometabolic pipelineStrategic or Co-development Partner · 25 February 2026Collaboration announced February 2026 to discover and develop orally available small-molecule inhibitors targeting mitochondrial dysfunction in cardiometabolic diseases, with initial focus on diabetic cardiovascular disease. Combines Chemify's ML-based Chemputation platform for molecular design and automated synthesis with Sanacor's translational biology platform led by CEO and Co-founder Dr. Michael Widlansky.
• Prepaire Labsflagship strategic partner for opioid programsStrategic or Co-development Partner · 18 January 2024Expanded partnership announced January 2024 with the 'Toxifree' program to develop a novel class of digitally discovered non-addictive opioids and addiction treatments in response to FDA's CDER guidance on stimulant use disorder. Combines Chemify's Chemputation platform with Prepaire's open-architecture drug discovery platform. Chemify entitled to at least USD $30 million in payments and pre-negotiated clinical/regulatory milestones per developed molecule, plus single-digit royalties.
• Dewpoint Therapeuticsflagship strategic partner for oncology and neurodegenerationStrategic or Co-development Partner · 12 September 2023Partnership announced September 2023 to design, discover, and automatically synthesize novel molecules against condensate targets in Dewpoint's oncology and neurodegeneration pipeline. Combines Chemify's chemistry AI and automation platform with Dewpoint's condensate biology platform. Chemify receives pre-negotiated success-driven payments and tiered royalties; Dewpoint may exercise an option to acquire compounds.
• Lgeniacore co-development partner for tb programStrategic or Co-development PartnerCollaborating with Chemify on the Bill & Melinda Gates Foundation–funded tuberculosis drug discovery program. Lgenia provides known Mtb NadE inhibitor scaffolds (Wang series) and disease biology expertise; Chemify designs and synthesises improved analogues via the Chemputation platform.
• University of Glasgowfoundational academic partner (spin-out origin)OthersChemify was founded in 2022 as a spin-out from the University of Glasgow, building on 20+ years of research from the Cronin Group led by founder and CEO Professor Lee Cronin (Regius Chair of Chemistry). The company's registered office is at the School of Chemistry, University of Glasgow, G12 8QQ.

Scale indicators8 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Exscientia: AI-driven drug discovery company using automated design-synthesis-test cycles to develop small-molecule therapeutics for pharma partners. Operates a similar partnership-based business model with upfront, milestone, and royalty economics, directly competing with Chemify for enterprise pharma AI chemistry engagements.
• Insitro: Machine-learning-driven drug discovery company combining automated wet-lab experimentation with predictive models for small-molecule and target discovery. Targets similar pharma partnership economics and operates at the intersection of AI and laboratory automation, comparable to Chemify's design-make-test-analyze positioning.
• Iambic Therapeutics: AI-driven drug discovery company combining machine learning models with automated chemistry to design and synthesize novel small molecules. Directly comparable to Chemify in using AI-generated designs executed through automated synthesis, and competes for similar pharma partnership deals.
• Valo Health: AI-enabled drug discovery platform combining patient data, molecular dynamics, and automated chemistry to develop small-molecule therapeutics. Uses a similar partnership-driven model with pharma and operates at the AI-chemistry intersection that Chemify targets.

Broad incumbents

• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput wet-lab automation with machine learning across multiple therapeutic areas. Larger and publicly listed, Recursion competes with Chemify for pharma AI partnerships but operates a much broader biology-first platform rather than chemistry-focused programmable synthesis.
• Schrödinger: Computational chemistry platform providing physics-based molecular simulation and predictive modeling for drug discovery and materials science. Overlaps with Chemify on AI-driven molecular design and route planning but is a broader, more established software-first incumbent without the physical robotic synthesis layer.
• Isomorphic Labs: Alphabet-owned drug discovery company spun out of DeepMind, applying AI to molecular design and protein structure prediction. A well-capitalized broad incumbent in AI drug discovery whose strategy intersects with Chemify's generative chemistry ambitions, though without an equivalent physical synthesis automation layer.

Emerging players

• Cradle Bio: Generative AI company focused on protein and biologics design rather than small molecules. An emerging player in the broader AI-driven bio-design space with partial overlap to Chemify's generative design ambitions but a different molecular modality.
• Emerald Cloud Lab: Remote, automated wet-lab facility that allows scientists to run experiments through software interfaces. Shares Chemify's philosophy of fully automated lab execution but focuses on general life-science experimentation rather than small-molecule synthesis programming.

Others

• Benchling: Cloud-based R&D informatics platform widely adopted by biotech and pharma for experiment tracking, molecular biology, and chemistry data management. Not a direct competitor but an adjacent enabling technology ecosystem participant that Chemify customers may already use for laboratory data infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chemify-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemify